The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease

被引：1
|
作者：
Kawada, Tomoyuki [1 ]
机构：
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
来源：
CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2016年 / 20卷 / 01期
关键词：
Estimated glomerular filtration rate; Autosomal dominant polycystic kidney disease; Tolvaptan; Validity;
D O I：
10.1007/s10157-015-1134-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [21] Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
    Shimoda, Naoko
    Ikeda, Mariko
    Yan, Tomohiro
    Kawasaki, Sayuri
    Hirama, Akio
    Kashiwagi, Tetsuya
    Sakai, Yukinao
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2022, 89 (03) : 287 - 294
  • [22] Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
    Moriyama, Tomofumi
    Nakayama, Yosuke
    Soejima, Mikiko
    Yokota, Yunosuke
    Ota, Kanji
    Ito, Sakuya
    Kodama, Goh
    Nakamura, Nao
    Kurokawa, Yuka
    Yano, Junko
    Ueda, Utako
    Takamiya, Yoshimi
    Kaida, Yusuke
    Hazama, Takuma
    Shibata, Ryo
    Koda, Yoshiro
    Fukami, Kei
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (03) : 251 - 260
  • [23] The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
    Tarabzuni, Ola
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [24] Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
    Tomofumi Moriyama
    Yosuke Nakayama
    Mikiko Soejima
    Yunosuke Yokota
    Kanji Ota
    Sakuya Ito
    Goh Kodama
    Nao Nakamura
    Yuka Kurokawa
    Junko Yano
    Utako Ueda
    Yoshimi Takamiya
    Yusuke Kaida
    Takuma Hazama
    Ryo Shibata
    Yoshiro Koda
    Kei Fukami
    Clinical and Experimental Nephrology, 2021, 25 : 251 - 260
  • [25] Kidney volume and function in autosomal dominant polycystic kidney disease
    Higashihara, Eiji
    Nutahara, Kikuo
    Okegawa, Takatsugu
    Shishido, Toshihide
    Tanbo, Mitsuhiro
    Kobayasi, Kuninori
    Nitadori, Toshiaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (01) : 157 - 165
  • [26] Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease
    Torres, Vicente E.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (01) : 30 - 34
  • [27] Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era
    Lapao, Tania
    Barata, Rui
    Jorge, Cristina
    Flores, Carlos
    Calado, Joaquim
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (03)
  • [28] Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease
    Akihisa, Taro
    Kataoka, Hiroshi
    Makabe, Shiho
    Manabe, Shun
    Yoshida, Rie
    Ushio, Yusuke
    Sato, Masayo
    Tsuchiya, Ken
    Mochizuki, Toshio
    Nitta, Kosaku
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2022, 26 (06) : 540 - 551
  • [29] Kidney volume and function in autosomal dominant polycystic kidney disease
    Eiji Higashihara
    Kikuo Nutahara
    Takatsugu Okegawa
    Toshihide Shishido
    Mitsuhiro Tanbo
    Kuninori Kobayasi
    Toshiaki Nitadori
    Clinical and Experimental Nephrology, 2014, 18 : 157 - 165
  • [30] Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease
    Taro Akihisa
    Hiroshi Kataoka
    Shiho Makabe
    Shun Manabe
    Rie Yoshida
    Yusuke Ushio
    Masayo Sato
    Ken Tsuchiya
    Toshio Mochizuki
    Kosaku Nitta
    Clinical and Experimental Nephrology, 2022, 26 : 540 - 551
12345